LONA.US LeonaBio, Inc.
- Market cap
- USD 32.7M
- P/E
- -
- P/B
- 0.97x
- ROE
- -309.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is LONA.US undervalued?
Graham numberThe Graham number of LeonaBio, Inc. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
LeonaBio, Inc. fundamental analysis
No fundamental analysis for LeonaBio, Inc. yet.
LeonaBio, Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for th…
Full company profileLeonaBio, Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
LeonaBio, Inc. annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | - | - | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | - | - | -2.00M | -479K | - | - | - | -68.1M | -916K |
| Operating Income | -5.01M | -5.45M | -20.0M | -64.0M | -104M | -125M | -101M | -102M | -75.2M |
| EBITDA | -79.0K | -4.81M | -19.6M | -54.4M | -88.0M | -126M | -95.8M | -33.2M | -73.4M |
| Net Income | -5.10M | -5.16M | -20.0M | -54.9M | -95.6M | -118M | -96.9M | -106M | -104M |
| EPS | -1.56 | -1.58 | -6.14 | -15 | -25 | -31 | -25 | -25 | -24 |
| Balance Sheet | |||||||||
| Total Assets | 4.93M | 2.19M | 280M | 332M | 258M | 160M | 58.8M | 92.2M | 56.9M |
| Total Liabilities | 19.8M | 21.9M | 5.28M | 10.9M | 23.0M | 30.1M | 13.9M | 64.4M | 23.3M |
| Shareholders' Equity | -14.9M | -19.7M | 274M | 321M | 235M | 130M | 44.8M | 27.8M | 33.6M |
| Cash & Short-term Investments | 4.82M | 2.06M | 185M | 254M | 200M | 147M | 51.3M | 88.3M | 51.1M |
| Total Debt | 722K | 1.55M | 1.00M | 1.92M | 1.91M | 1.59M | 1.22M | 803K | 577K |
| Cash Flow | |||||||||
| Operating Cash Flow | -4.48M | -3.71M | -24.1M | -43.1M | -72.5M | -101M | -97.2M | -45.7M | -75.7M |
| Capital Expenditure | 0.00 | 0.00 | 2.32M | 1.57M | 1.14M | 304K | 33.0K | 0.00 | 0.00 |
| Free Cash Flow | -4.48M | -3.71M | -26.4M | -44.7M | -73.6M | -101M | -97.2M | -45.7M | -75.7M |
| Ratios | |||||||||
| ROE | - | - | -7.3% | -17.1% | -40.7% | -90.4% | -216.2% | -380.0% | -309.3% |
| ROA | -103.3% | -235.8% | -7.1% | -16.5% | -37.0% | -73.4% | -164.9% | -114.6% | -182.6% |
| Debt to Equity | - | - | 0.00x | 0.01x | 0.01x | 0.01x | 0.03x | 0.03x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Debt to Equity
- Total debt divided by shareholders' equity.
LeonaBio, Inc. dividends
LeonaBio, Inc. has not paid dividends in the last 8 fiscal years.
Last stock split: 1:10 on Sep 18, 2025.
Who owns LeonaBio, Inc.
- Insiders 37.50%
- Institutions 62.50%
- Public & others 0.00%
- Shares outstanding 9.42M
- Free float 3.45M
Top funds holding LONA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Vanguard MStar Total Stk Mkt Idx Invest | 183K | 1.95% | 0.00% | Sep 2026 |
| Simplify Propel Opportunities ETF | 100K | 1.06% | -1.55% | Oct 2026 |
| Fidelity Extended Market Index | 35.5K | 0.38% | -0.38% | Sep 2026 |
| iShares Micro-Cap ETF | 19.6K | 0.21% | 0.00% | Oct 2026 |
| Fidelity Total Market Index | 11.8K | 0.13% | 0.00% | Sep 2026 |
| Fidelity Series Total Market Index | 10.0K | 0.11% | 0.00% | Sep 2026 |
| Fidelity Nasdaq Composite Index | 7.72K | 0.08% | 0.00% | Aug 2026 |
| Vanguard MStar Inst Ttl StkMktIdxInstlPl | 5.99K | 0.06% | 0.00% | Sep 2026 |
| DFA US Micro Cap I | 3.77K | 0.04% | 0.00% | Sep 2026 |
| DFA U.S. Core Equity 1 I | 3.64K | 0.04% | +256.02% | Sep 2026 |
| Vanguard Balanced Index Inv | 3.60K | 0.04% | 0.00% | Sep 2026 |
| Dimensional US Core Equity 1 ETF | 2.61K | 0.03% | 0.00% | Sep 2026 |
| DFA U.S. Vector Equity I | 1.67K | 0.02% | +8.89% | Sep 2026 |
| 1290 VT Micro Cap K | 1.48K | 0.02% | 0.00% | Sep 2026 |
| Dimensional Global Core Equity USD Acc | 1.36K | 0.01% | -0.29% | Sep 2026 |
| Vanguard U.S. Eq Idx £ Acc | 1.33K | 0.01% | 0.00% | Sep 2026 |
| DFA US Social Core Equity 2 Portfolio | 1.25K | 0.01% | 0.00% | Sep 2026 |
| DFA US Sustainability Core 1 | 1.25K | 0.01% | 0.00% | Sep 2026 |
| Dimensional Gl Cor Eq LC ESG Sc USD A | 1.13K | 0.01% | -0.44% | Sep 2026 |
| Dimensional US Core Equity 2 ETF | 1.05K | 0.01% | 0.00% | Oct 2026 |
Top institutions holding LONA.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Perceptive Advisors LLC | 1.86M | 19.73% | 0.00% | Jun 2026 |
| Kalehua Capital Management LLC | 787K | 8.36% | 0.00% | Jun 2026 |
| ADAR1 Capital Management LLC | 777K | 8.25% | +6.82% | Jun 2026 |
| COMMODORE CAPITAL LP | 464K | 4.93% | 0.00% | Jun 2026 |
| TCG Crossover Management, LLC | 464K | 4.93% | 0.00% | Jun 2026 |
| NEA Management Company, LLC | 464K | 4.93% | 0.00% | Jun 2026 |
| Spruce Street Capital LP | 394K | 4.18% | 0.00% | Sep 2026 |
| Blackstone Inc | 325K | 3.45% | 0.00% | Jun 2026 |
| Adage Capital Partners Gp LLC | 300K | 3.18% | 0.00% | Jun 2026 |
| Vanguard Capital Management, LLC | 275K | 2.92% | +41.32% | Jun 2026 |
| Seven Fleet Capital Management LP | 154K | 1.64% | -6.39% | Jun 2026 |
| Propel Bio Management LLC | 149K | 1.58% | 0.00% | Jun 2026 |
| Simplify Asset Management Inc. | 149K | 1.58% | 0.00% | Sep 2026 |
| Geode Capital Management, LLC | 80.4K | 0.85% | +0.12% | Jun 2026 |
| BlackRock Inc | 79.2K | 0.84% | +41.27% | Jun 2026 |
| Renaissance Technologies Corp | 57.0K | 0.60% | -26.42% | Sep 2026 |
| Vanguard Fiduciary Trust Co | 42.8K | 0.45% | +6.93% | Jun 2026 |
| Bank of America Corp | 32.6K | 0.35% | -0.03% | Jun 2026 |
| Millennium Management LLC | 32.5K | 0.34% | +2.44% | Jun 2026 |
| Laird Norton Tyee Trust Co | 21.8K | 0.23% | 0.00% | Jun 2026 |
LeonaBio, Inc. company profile
- Company name
- LeonaBio, Inc.
- Ticker
- LONA.US
- Exchange
- USA Stocks
- Listed since
- Sep 18, 2020
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Employees
- 19
- Fiscal year end
- December
- Address
- 18706 North Creek Parkway, Bothell, WA, United States, 98011
- Phone
- 425 620 8501
- Website
- leonabio.com
About LeonaBio, Inc.
LeonaBio, Inc., clinical-stage biopharmaceutical company, engages in the development of novel therapeutics for high unmet medical needs, including treatment-resistant metastatic breast cancer and amyotrophic lateral sclerosis. The company's lead products include lasofoxifene and ATH-1105, a novel small molecule therapies with the potential to address devastating diseases where current treatment options are limited or ineffective. Its product pipeline includes ATH-1105 for the treatment of amyotrophic lateral sclerosis, which is in phase 1 clinical trial; ATH-1020 for the treatment of diabetic neuropathy, which is in phase 1 clinical trial; and ATH-1017 for the treatment of Alzheimer's disease and Parkinson's disease, which is in phase 2 clinical trial, as well as early compounds which is in preclinical phase. The company was formerly known as Athira Pharma, Inc. and changed its name to LeonaBio, Inc. in January 2026. LeonaBio, Inc. was incorporated in 2011 and is headquartered in Bothell, Washington.
LeonaBio, Inc. management
7- Dr. Mark J. Litton M.B.A., Ph.D.President, CEO & Director · born 1968
- Mr. Mark F. Worthington J.D.General Counsel, Chief Compliance Officer & Corporate Secretary · born 1966
- Dr. Javier San Martin M.D.Chief Medical Officer · born 1965
- Mr. Robert RenningerChief Financial Officer · born 1985
- Dr. Kevin Church Ph.D.Chief Scientific Officer · born 1985
- Ms. Julie RathbunHead of Investor Relations
- Mr. Mark F. Kubik M.B.A.Chief Business Officer · born 1965